STN:BL 125259
Proper Name:Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant
Tradename: Cervarix
Manufacturer: GlaxoSmithKline Biologicals
Indications:

• Prevention of cervical cancer, cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and cervical intraepithelial neoplasia (CIN) grade 1, caused by oncogenic human papillomavirus (HPV) types 16 and 18, in females9 through 25 years of age

Product Information

• Package Insert & Patient Information- Cervarix

Supporting Documents

• Approval History, Letters, Reviews, and Related Documents - Cervarix
• Supporting Documents older than three years - Cervarix

Related Information

• FDA Approves New Vaccine for Prevention of Cervical Cancer - ARCHIVED